Divesiran - Silence Therapeutics
Alternative Names: SLN-124Latest Information Update: 12 Dec 2024
Price :
$50 *
At a glance
- Originator Intradigm Corporation
- Developer Silence Therapeutics
- Class Antineoplastics; Hexosamines; Small interfering RNA
- Mechanism of Action RNA interference; TMPRSS6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Polycythaemia vera
- Phase I Myelodysplastic syndromes
- No development reported Haemochromatosis; Iron overload
- Discontinued Beta-thalassaemia
Most Recent Events
- 09 Dec 2024 Divesiran - Silence Therapeutics receives Fast Track designation for Polycythaemia vera [SC,Injection] in USA
- 09 Dec 2024 Updated efficacy and adverse event data from a phase I/II trial in Polycythemia released by Silence Therapeutics
- 27 Jun 2024 Efficacy, adverse events and pharmacodynamics data from a phase I/II clinical trials in Polycythaemia vera released by Silence Therapeutics